Eastgate Biotech Corp. (ETBI) Stock

About Eastgate Biotech Corp.

EastGate Biotech Corp. is a pharmaceutical company specializing in the production and distribution of nutraceuticals. These products are rooted in natural therapies and designed for natural absorption within the body. The firm employs cutting-edge nanotechnologies to provide healthier options compared to conventional pharmaceuticals, which often lead to detrimental side effects and unforeseen issues for individuals seeking to achieve and maintain good health. Among its diverse product line are E-Drops NANO, Essential D, GluCora, VCleanzz, Cleanezze, and Warts X. EastGate Biotech's development process involves integrating product components into various nano-sized delivery systems. These systems include oil droplets (nanoemulsions), polymeric particles (nanoparticles), and complex combinations of polymers, lipids, and surfactants (such as hybrid nanoparticles, nanocapsules, and mixed micelles). The company has operational bases in prominent cities including New York, London SF, Cockfosters BP, Los Angeles, Chicago, and Las Vegas.

Eastgate Biotech Corp. (ETBI) stock trades at $0.00 with a market capitalization of $6.17M. The stock is valued at a price-to-earnings (P/E) ratio of -1.58, price-to-book of -0.59, price-to-sales of 23.06. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, Eastgate Biotech Corp. generates a return on equity (ROE) of 40.00% — well above the market average, a sign of a high-quality business, return on capital employed of 33.81%, an operating margin of -7439.63%, a net profit margin of 0.00%.

Official website: www.EastGateBiotech.com